PPD, Inc. has entered an agreement with Janssen Pharmaceutica to develop and commercialize two Phase II therapeutic compounds, one for diarrhea-predominant irritable bowel syndrome (IBS-d) and one for complicated skin and skin structure and respiratory infections. PPD in-licensed the two compounds and will advance them through Phase II development. At the completion of Phase II, Janssen will have the option to resume development and commercialization. In exchange, PPD will receive as much as ...